

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
AUSBORN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/014682

FILED: 23 DECEMBER 2004

U.S. APPLICATION NO: 10/581,937

35 USC §371 DATE: 7 JUNE 2006

FOR: PHARMACEUTICAL COMPOSITIONS

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 7, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Some of the listed references were cited in a search report in a corresponding British application. Copies of these references and the search report are enclosed herewith.

With respect to CN1129947A, a copy of the PCT application abstract in English for WO95/06077 is enclosed herewith. This English abstract provides a concise explanation of the relevance. Also, copies of the other references cited in the international prosecution are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08a form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7877



---

John W. Kung  
Attorney for Applicants  
Reg. No. 44,199

Date: October 1, 2008